Smith & Nephew (NYSE:SNN) Earns Hold Rating from Canaccord Genuity Group

Canaccord Genuity Group reiterated their hold rating on shares of Smith & Nephew (NYSE:SNN - Free Report) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $27.00 target price on the medical equipment provider's stock.

A number of other analysts have also issued reports on the stock. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. UBS Group cut shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Smith & Nephew has a consensus rating of "Hold" and a consensus price target of $27.00.

Smith & Nephew Trading Down 1.3 %

Shares of SNN stock traded down $0.38 on Monday, reaching $28.08. 443,227 shares of the company's stock were exchanged, compared to its average volume of 817,590. The company's fifty day simple moving average is $26.68 and its 200 day simple moving average is $27.11. Smith & Nephew has a 52 week low of $23.65 and a 52 week high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $12.27 billion, a PE ratio of 13.00, a P/E/G ratio of 1.26 and a beta of 0.83.

Remove Ads

Smith & Nephew Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be issued a $0.447 dividend. The ex-dividend date is Friday, March 28th. This represents a dividend yield of 2.5%. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. Smith & Nephew's payout ratio is currently 41.20%.

Hedge Funds Weigh In On Smith & Nephew

Several institutional investors have recently bought and sold shares of the business. River Road Asset Management LLC increased its holdings in shares of Smith & Nephew by 64.0% in the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock valued at $49,947,000 after acquiring an additional 792,829 shares during the period. J. Goldman & Co LP purchased a new position in Smith & Nephew in the fourth quarter valued at about $47,700,000. Brandes Investment Partners LP raised its holdings in Smith & Nephew by 11.4% in the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock worth $33,504,000 after purchasing an additional 138,994 shares in the last quarter. Clark Estates Inc. NY lifted its position in shares of Smith & Nephew by 16.8% during the fourth quarter. Clark Estates Inc. NY now owns 800,000 shares of the medical equipment provider's stock valued at $19,664,000 after buying an additional 115,000 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Smith & Nephew by 11.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 535,350 shares of the medical equipment provider's stock valued at $13,159,000 after buying an additional 57,014 shares in the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.